"Dihydrotestosterone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A potent androgenic metabolite of TESTOSTERONE. It is produced by the action of the enzyme 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE.
| Descriptor ID |
D013196
|
| MeSH Number(s) |
D04.210.500.054.040.248 D06.472.334.851.968.964
|
| Concept/Terms |
Dihydrotestosterone- Dihydrotestosterone
- 5 alpha-Dihydrotestosterone
- 5 alpha Dihydrotestosterone
- Androstanolone
- 5-alpha Dihydrotestosterone
- Dihydrotestosterone, 5-alpha
- Stanolone
- 5-alpha-DHT
- 5 alpha DHT
- 17beta-Hydroxy-5alpha-Androstan-3-One
- 17beta Hydroxy 5alpha Androstan 3 One
|
Below are MeSH descriptors whose meaning is more general than "Dihydrotestosterone".
Below are MeSH descriptors whose meaning is more specific than "Dihydrotestosterone".
This graph shows the total number of publications written about "Dihydrotestosterone" by people in this website by year, and whether "Dihydrotestosterone" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 1 | 2 |
| 1999 | 0 | 3 | 3 |
| 2000 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2007 | 0 | 2 | 2 |
| 2010 | 0 | 2 | 2 |
| 2017 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dihydrotestosterone" by people in Profiles.
-
Hormonal modulation of ESR1 mutant metastasis. Oncogene. 2021 02; 40(5):997-1011.
-
Intracrine androgen biosynthesis in renal cell carcinoma. Br J Cancer. 2017 Mar 28; 116(7):937-943.
-
Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice. Prostate. 2010 Oct 01; 70(14):1575-85.
-
Thrombospondin-1 regulates the normal prostate in vivo through angiogenesis and TGF-beta activation. Lab Invest. 2010 Jul; 90(7):1078-90.
-
Prolongation of off-cycle interval by finasteride is not associated with survival improvement in intermittent androgen deprivation therapy in LNCaP tumor model. Prostate. 2010 Feb 01; 70(2):147-54.
-
Novel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer. Cancer Sci. 2008 Jan; 99(1):81-6.
-
Regulation of catechol O-methyltransferase expression in granulosa cells: a potential role for follicular arrest in polycystic ovary syndrome. Fertil Steril. 2008 May; 89(5 Suppl):1414-21.
-
Microcephaly, jejunal atresia, aberrant right bronchus, ocular anomalies, and XY sex reversal. Am J Med Genet A. 2004 Mar 15; 125A(3):293-8.
-
Safety and pharmacokinetic study with escalating doses of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy male volunteers. Clin Invest Med. 2000 Oct; 23(5):300-10.
-
Growth hormone and insulin-like growth factors have different effects on sebaceous cell growth and differentiation. Endocrinology. 1999 Sep; 140(9):4089-94.